Denali Therapeutics begins marketing application for genetic disorder drug, shares rise
Brief: Denali Therapeutics Announces Initiation Of BLA Filing For Accelerated Approval Of Tividenofusp Alfa For Treatment Of Hunter Syndrome
Brief: Denali Therapeutics Inc To Discontinue Active Treatment Extension In Regimen G
Brief: Denali Therapeutics Files For Mixed Shelf Size Not Disclosed - SEC Filing
Denali Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Denali Therapeutics Q4 Operating Income USD -129.846 Million
Brief: Denali Therapeutics Announces Primary Analysis & Long-Term Follow-Up Of Phase 1/2 Study In Hunter Syndrome With Tividenofusp Alfa
Brief: Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities
Brief: Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted To Tividenofusp Alfa For The Treatment Of Hunter Syndrome (MPS II)
U.S. STOCKS ON THE MOVE-Annovis Bio, Hoth Therapeutics, Digital Realty
U.S. STOCKS ON THE MOVE-Annovis Bio, Hoth Therapeutics, Digital Realty
U.S. STOCKS ON THE MOVE-Hims & Hers, UniFirst, Carvana
Denali Therapeutics falls after ALS drug fails in mid-to-late stage trial
U.S. RESEARCH ROUNDUP-CNX Resources, Inari Medical, Royal Gold
Brief: Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
Denali Therapeutics down after its ALS drug fails in mid-to-late stage trial
Denali Therapeutics' ALS drug fails in mid-to-late stage trial (updated)
Denali Therapeutics ALS drug fails in mid-stage trial
Denali Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary